Glaxo Smith Kline (BIOC.CA) Reports Year Ended 31/12/2023 Consolidated Results
Company Name : Glaxo Smith Kline
ISIN Code : EGS38171C012
Currency : EGP
F/S Consolidated Period : From 01/01/2023 To 31/12/2023
Net Profit : 60,471,827
F/S Consolidated Period : From 01/01/2022 To 31/12/2022
Net Comparative Profit : 735,396,533
Audit Status : Audited
Source : Glaxo Smith Kline
The BoD Report (1,645 KB)
ISIN Code : EGS38171C012
Currency : EGP
F/S Consolidated Period : From 01/01/2023 To 31/12/2023
Net Profit : 60,471,827
F/S Consolidated Period : From 01/01/2022 To 31/12/2022
Net Comparative Profit : 735,396,533
Audit Status : Audited
Source : Glaxo Smith Kline
The BoD Report (1,645 KB)
Comments